Telephone
61.02.9099.4750
Address
Level 1 3-5 George Street Leichardt, New South Wales (NSW) 2040
Description
Atomo Diagnostics Ltd. engages in manufacture, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. It offers its products through the AtomoRapid range of RDT platforms. The company was founded by John Kelly in 2010 and is headquartered in Leichhardt, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.1
Trade Value (12mth)
AU$16,531.00
1 week
4.76%
1 month
0%
YTD
-60%
1 year
-58.49%
All time high
0.63
EPS 3 yr Growth
-32.800%
EBITDA Margin
-320.30%
Operating Cashflow
-$6m
Free Cash Flow Return
-29.30%
ROIC
-49.90%
Interest Coverage
-543.60
Quick Ratio
5.50
Shares on Issue (Fully Dilluted)
571m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 July 20 |
Atomo to present at the NWR Small Cap Conference
×
Atomo to present at the NWR Small Cap Conference |
31 August 20 |
Appendix 4E & Annual Financial Report
×
Appendix 4E & Annual Financial Report |
31 August 20 |
FY20 Results Presentation
×
FY20 Results Presentation |
30 December 21 |
Response to ASX Price Query
×
Response to ASX Price Query |
30 April 20 |
Atomo to present at Virtual Health Conference
×
Atomo to present at Virtual Health Conference |
29 September 23 |
2023 Notice of Annual General Meeting
×
2023 Notice of Annual General Meeting |
29 July 22 |
Appendix 4C - 30 June 2022
×
Appendix 4C - 30 June 2022 |
29 July 22 |
Quarterly Activity Report - 30 June 2022
×
Quarterly Activity Report - 30 June 2022 |
29 July 20 |
Investor Presentation 29 July 2020
×
Investor Presentation 29 July 2020 |
29 April 22 |
Notification regarding unquoted securities - AT1
×
Notification regarding unquoted securities - AT1 |
28 October 22 |
Investor Webinar and Presentation
×
Investor Webinar and Presentation |
28 October 21 |
Managing Director's AGM Presentation
×
Managing Director's AGM Presentation |
28 July 23 |
Update - Proposed issue of securities - AT1
×
Update - Proposed issue of securities - AT1 |
28 February 23 |
Significant Purchase Order for HIV Self-Tests for Europe
×
Significant Purchase Order for HIV Self-Tests for Europe |
28 April 23 |
Becoming a substantial holder
×
Becoming a substantial holder |
27 September 21 |
Atomo 2021 Annual General Meeting
×
Atomo 2021 Annual General Meeting |
27 October 22 |
2022 Annual General Meeting - Chairman's Address
×
2022 Annual General Meeting - Chairman's Address |
27 October 22 |
2022 Annual General Meeting - MD & CEO's Address
×
2022 Annual General Meeting - MD & CEO's Address |
27 October 22 |
Results of 2022 Annual General Meeting
×
Results of 2022 Annual General Meeting |
27 October 22 |
Notification regarding unquoted securities - AT1
×
Notification regarding unquoted securities - AT1 |
27 October 22 |
Change of Director's Interest Notice - John Kelly
×
Change of Director's Interest Notice - John Kelly |
27 May 22 |
Change in substantial holding
×
Change in substantial holding |
27 July 23 |
Appendix 4C - 30 June 2023
×
Appendix 4C - 30 June 2023 |
27 July 23 |
Quarterly Activity Report - 30 June 2023
×
Quarterly Activity Report - 30 June 2023 |
27 July 20 |
Atomo to present at IRD Invest Virtual Investor Conference
×
Atomo to present at IRD Invest Virtual Investor Conference |
27 January 23 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
27 January 23 |
Appendix 4C - 31 December 2022
×
Appendix 4C - 31 December 2022 |
27 January 23 |
Quarterly Activity Report - 31 December 2022
×
Quarterly Activity Report - 31 December 2022 |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.